Citadel Securities Starts Vertex (VRTX) at Neutral; Incivek Launch Going Strong, But Appears Priced In
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $77.87 -1.18%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade VRTX Now!
Citadel Securities initiates coverage on Vertex (NASDAQ: VRTX) with a Neutral. PT $46.00.
Citadel analyst says, "The Incivek launch appears to be progressing well with initial prescription data showing both a meaningful uptake for the therapy, and growth in the HCV treatment market, in our view. However, Street consensus appears to have priced in widespread adoption of the therapy, making it difficult for Incivek sales to outperform expectations. Importantly, early prescription data reinforce our view that Incivek will be more broadly considered than Merck’s Victrelis given what we view to be a less complicated treatment regimen and numerically better data."
For more ratings news on Vertex click here and for the rating history of Vertex click here.
Shares of Vertex closed at $43.00 yesterday, with a 52 week range of $32.08-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Citadel analyst says, "The Incivek launch appears to be progressing well with initial prescription data showing both a meaningful uptake for the therapy, and growth in the HCV treatment market, in our view. However, Street consensus appears to have priced in widespread adoption of the therapy, making it difficult for Incivek sales to outperform expectations. Importantly, early prescription data reinforce our view that Incivek will be more broadly considered than Merck’s Victrelis given what we view to be a less complicated treatment regimen and numerically better data."
For more ratings news on Vertex click here and for the rating history of Vertex click here.
Shares of Vertex closed at $43.00 yesterday, with a 52 week range of $32.08-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold
- Credit Suisse Starts Dr Pepper Snapple (DPS) at Neutral
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
